GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (LSE:OBI) » Definitions » EV-to-EBITDA

Ondine Biomedical (LSE:OBI) EV-to-EBITDA : -1.91 (As of Jun. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ondine Biomedical's enterprise value is £20.75 Mil. Ondine Biomedical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was £-10.88 Mil. Therefore, Ondine Biomedical's EV-to-EBITDA for today is -1.91.

The historical rank and industry rank for Ondine Biomedical's EV-to-EBITDA or its related term are showing as below:

LSE:OBI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.58   Med: -0.9   Max: 0.04
Current: -1.91

During the past 13 years, the highest EV-to-EBITDA of Ondine Biomedical was 0.04. The lowest was -15.58. And the median was -0.90.

LSE:OBI's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.15 vs LSE:OBI: -1.91

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Ondine Biomedical's stock price is £0.0825. Ondine Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.060. Therefore, Ondine Biomedical's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Ondine Biomedical EV-to-EBITDA Historical Data

The historical data trend for Ondine Biomedical's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical EV-to-EBITDA Chart

Ondine Biomedical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -3.19 -2.85

Ondine Biomedical Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.19 - -2.85 -

Competitive Comparison of Ondine Biomedical's EV-to-EBITDA

For the Biotechnology subindustry, Ondine Biomedical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ondine Biomedical's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's EV-to-EBITDA falls into.



Ondine Biomedical EV-to-EBITDA Calculation

Ondine Biomedical's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=20.752/-10.877
=-1.91

Ondine Biomedical's current Enterprise Value is £20.75 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ondine Biomedical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was £-10.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ondine Biomedical  (LSE:OBI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Ondine Biomedical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0825/-0.060
=At Loss

Ondine Biomedical's share price for today is £0.0825.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ondine Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.060.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Ondine Biomedical EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ondine Biomedical (LSE:OBI) Business Description

Traded in Other Exchanges
Address
1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical (LSE:OBI) Headlines

No Headlines